HIV-1–Specific CD8 T Cells Exhibit Limited Cross-Reactivity during Acute Infection
Author(s) -
Victor Y. Du,
Anju Bansal,
Jonathan M. Carlson,
Jesus F. Salazar-Gonzalez,
Maria G. Salazar,
Kristin Ladell,
Stéphanie Gras,
Tracy M. Josephs,
Sonya L. Heath,
David A. Price,
Jamie Rossjohn,
Eric Hunter,
Paul Goepfert
Publication year - 2016
Publication title -
the journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.737
H-Index - 372
eISSN - 1550-6606
pISSN - 0022-1767
DOI - 10.4049/jimmunol.1502411
Subject(s) - human immunodeficiency virus (hiv) , cytotoxic t cell , virology , cd8 , immunology , cross reactivity , medicine , biology , immune system , cross reactions , in vitro , antibody , genetics
Prior work has demonstrated that HIV-1-specific CD8 T cells can cross-recognize variant epitopes. However, most of these studies were performed in the context of chronic infection, where the presence of viral quasispecies makes it difficult to ascertain the true nature of the original antigenic stimulus. To overcome this limitation, we evaluated the extent of CD8 T cell cross-reactivity in patients with acute HIV-1 clade B infection. In each case, we determined the transmitted founder virus sequence to identify the autologous epitopes restricted by individual HLA class I molecules. Our data show that cross-reactive CD8 T cells are infrequent during the acute phase of HIV-1 infection. Moreover, in the uncommon instances where cross-reactive responses were detected, the variant epitopes were poorly recognized in cytotoxicity assays. Molecular analysis revealed that similar antigenic structures could be cross-recognized by identical CD8 T cell clonotypes mobilized in vivo, yet even subtle differences in a single TCR-accessible peptide residue were sufficient to disrupt variant-specific reactivity. These findings demonstrate that CD8 T cells are highly specific for autologous epitopes during acute HIV-1 infection. Polyvalent vaccines may therefore be required to provide optimal immune cover against this genetically labile pathogen.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom